Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study

Abstract
No abstract available
Funding Information
  • Anergis SA

This publication has 31 references indexed in Scilit: